MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Plerixafor
CAS No. : 110078-46-1
MCE 国际站：Plerixafor
产品活性：Plerixafor (AMD 3100) 是选择性的 CXCR4 拮抗剂，IC50 为 44 nM。Plerixafor 是一种免疫刺激剂和造血干细胞动员剂，也是 CXCR7 的变构激动剂。Plerixafor 抑制 HIV-1 和 HIV-2 的复制，EC50 为 1-10 nM。
研究领域：GPCR/G Protein | Immunology/Inflammation | Anti-infection
In Vitro: The CXCR4 inhibitor Plerixafor (AMD3100) is a potent inhibitor of CXCL12-mediated chemotaxis (IC50, 5.7 nM) with a potency slightly better than its affinity for CXCR4. Plerixafor interferes with the interaction of CXCR4 with its natural ligand, SDF-1 (CXCL12). Treating the cells with CCX771 or CXCL11 has no effect on CXCL12-mediated MOLT-4 or U937 TEM. In contrast, 10 μM Plerixafor inhibits CXCL12-mediated TEM in both cells lines
. Plerixafor prevents the infiltration of tumor-associated macrophages (TAMs) into the tumor tissues.
In Vivo: Plerixafor (2 mg/kg) administration to UUO mice exacerbates renal interstitial T cell infiltration, resulting in increased production of the pro-inflammatory cytokines IL-6 and IFN-γ and decreased expression of the anti-inflammatory cytokine IL-10.
Both perivascular and interstitial fibrosis are significantly reduced by the CXCR4 antagonist, Plerixafor (AMD3100) at 8 weeks. LD50, mouse, SC: 16.3 mg/kg; LD50, rat, SC: >50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | GPCR/G Protein Compound Library | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Antiviral Compound Library | Small Molecule Immuno-Oncology Compound Library | Peptidomimetic Library | Drug Repurposing Compound Library | Anti-diabetic Compound Library | Macrocyclic Compound Library | Endocrinology Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Targeted Diversity Library | Rare Diseases Drug Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Pulmonary Fibrosis Compound Library | Chemokine Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Cytokine Inhibitors Library | Extracellular Vesicles (EVs) Compound Library | Multi-Target Compound Library | Radioprotector Library | Bioactive Compound Library Max | Chloroquine | Doxorubicin hydrochloride | 5-Fluorouracil | Q-VD-OPh | Valproic acid | Panobinostat | Shikonin | Probenecid | Kaempferol | Hydroxyurea | Dimethyl fumarate | Maraviroc | Baicalin | SB225002 | Birinapant | Flavopiridol | AMG 487 | Ritonavir | Ivermectin | Ebselen | Rolipram | Fasudil Hydrochloride | Reparixin | CK-666 | Plerixafor octahydrochloride | Lysozyme from chicken egg white | Kynurenic acid | Navarixin
热门产品线：重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
